Utilisation des héparines en pratique médicale courante

Sang Thrombose Vaisseaux

Volumn 8, Issue SPEC. ISS., 1996, Pages 5-13

  Aiach, M ^a   Boneu, B ^a   Potron, G ^a   Alexandre, P ^a   D'Azemar, P ^a   Boisseau, M ^a   Boyer Neuman, C ^a   Coeur, P ^a   Delobel, J ^a   Huet, Y ^a   Kher, A ^a   Jude, B ^a   Le Querrec, A ^a   Lorenzini, J ^a   Neuhart, E ^a   Pouzol, P ^a   Roul, C ^a   Schlegel, N ^a   Scrobohaci, M L ^a   Tobelem, G ^a   Toulemonde, F ^a   Wiesel, M C ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0007092237     PISSN: 09997385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Collins R, Scrimgeour A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 1988 ; 318 : 1162-73.
2. Leyvraz PF, Richard J, Bachmann F, et al. Adjusted versus Fixed doses subcutaneous heparin in the prevention of deep vein thrombosis after total hip replacement. N Engl J Med 1983 ; 309 : 954-8.
3. Bentley PG, Kakkar V, Scully MF, et al. An objective study of alternative methods of heparin administration. Thromb Res 1980 ; 18 : 177-87.
4. Andersson G, Fagrell B, Holmgren K, et al. Subcutaneous administration of heparin : a randomized comparison with intravenous administration of heparin to patients with deep vein thrombosis. Thromb Res 1982 ; 27 : 631-9.
5. Doyle DJ, Turpie AGG, Hirsh J, et al. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. Ann Int Med 1987 ; 107 : 441-5.
6. Hull R, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. N Engl J Med 1986 ; 315 : 1109-14.
7. Pini M, Pattachini C, Quintavella R, et al. Subcutaneous vs intravenous heparin in the treatment of deep venous thrombosis. A randomized clinical trial. Thromb Haemostas 1990 ; 64 : 222-6.
8. Contant G, Gouault-Heilmann M, Martinolli JL. Heparin inactivation during blood storage, its prevention by blood collection in critic acid, theopnylline, adenosine, dipyridamole-CTAD mixture. Thromb Res 1983; 31 : 365-74.
9. Holm HA, Abildgaard U, Kalvenes S, et al. The antithrombotic effect of heparin in deep venous thrombosis: relation to four heparin assays. Acta Med Scand 1984; 216 : 287-93.
10. Levine M, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute trial comparing activated large daily doses of heparin. Arch Int Med 1994; 154: 49-56.
11. Management of venous thromboembolism. Lancet 1988; i: 275-7.
12. Gallus A, Jackman J, Tillett J, et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986; II: 1293-6.
13. Hull R, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990 ; 322: 1260-4.
14. Hull R, Delmore T, Genton E, et al Low-dose heparin in the long term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-8.
15. Hull R, Delmore T, Carter C, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long term treatment of venous thrombosis. N Engl J Med 1982; 306: 189-94.
16. Dautzenberg MD, Bara L, Cornu P, et al. Specific anti Xa activity of LMWH (Kabi 2165, CY 216, PK 10169) against the first international standard or LMWH : a collaborative study. Thromb Haemostas 1990; 64: 490-1.
17. Vitoux JF, Aiach M, Roncato M, et al. Should thromboprophylactic dosage of low molecular weight heparin be adapted to patient's weight. Thromb Haemostas 1988; 59: 120.
18. Goudable C, Saivin S, Houin G, et al. Pharmacokinetics of a low molecular weight heporin (Fraxiparin®) in various stages of chronic renal failure. Nephron 1991; 59: 543-5.
19. Levine M, Planes A, Hirsh J, et al. The relationship between antifactor Xa level and clinical outcome in patients receiving low molecular weight enoxaparine to prevent deep vein thrombosis after hip replacement. Thromb Haemostas 1989 ; 62 : 940-4.
20. Leizorovicz A, Simonneau G, Decousus H, et al. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep vein thrombosis: a meta-analysis. Br Med J 1994; 309: 299-304.
21. Boneu B. Low molecular weight heparin: is monitoring needed? Thromb Haemostas 1994 ; 72 : 330-4.
22. Schmidt B Ofosu FA, Mitchell L, et al. Anticoagulant effects of heparin in neonatal plasma. Pediatr Res 1989 ; 25 : 405-8.
23. Kelton JG, Sheridon D, Brain H, et al. Clinical usefulness of testing for a heparin-dependent platelet aggregating factor in patients with suspected heparin associated thrombocytopenia. J Lab Clin Med 1984 ; 103 : 606-12.
24. Becker PS, Miller VY. Heparin-induced thrombocytopenia. Stroke 1989 ; 20 : 1449-59.
25. Amiral J, Bridey F, Wolf M, et al. Antibodies to macromolecular platelet Factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemostas 1995 ; 73 : 21-8.
26. Magnani HN. Heparin induced thrombocytopenia (HIT) : an overview of 230 patients treated with Orgaran® (ORG 10172). Thromb Haemostas 1993 ; 70 : 554-61.
27. Hirsh J, Raschke R, Warkentin TE, et al. Heparin : mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 1995 ; 108 : 258S-275S.